Measurements and outcomes
anxiety, non-migraine headache, Allodynia, allodynia, headache, migraine, depression
MIGRAINE, HEADACHE DISORDERS
All participants prospectively kept a 4-week diary, with daily registration of headache characteristics, accompanying symptoms and use of acute headache medication, during the baseline assessment period and the post treatment period (weeks 9–12). The diaries had to be sent in every week to ensure accuracy. Data (entry) was cross checked both manually (randomly) and electronically with fixed algorithms. Determination of migraine and non-migraine headache on any day was calculated by an algorithm based on the International Classification of Headache Disorders criteria. In addition, questionnaires were filled out at baseline regarding allodynia, depression and anxiety. Allodynia was questioned by the previously used and published Dutch Allodynia Symptom Checklist (ASC) [Primary outcome was reversion from chronic to episodic migraine (i.e., headache no longer fulfils criteria of chronic migraine) from baseline to the last 4 weeks of the treatment period (weeks 9–12). Secondary outcomes were i) ≥ 50% response in migraine days, i.e., reduction in monthly migraine days (MMD) of 50% or more; ii) reduction in number of monthly migraine days (MMD); iii) reduction in number of monthly headache days (MHD). A migraine day was defined as a day fulfilling criteria for migraine with or without aura, or treated with migraine specific acute medication [